Didier Mugabe (Mozambique)
Instituto Nacional de Saúde
National Health Observatory
Didier Mugabe, MD, MPH, is Medical Epidemiologist. He has a medical degree from Eduardo Mondlane University in Mozambique and a Master's degree in Public Health from Vanderbilt University in the United States. He has been working in HIV for over Six years, with a focus on the design, implementation, and evaluation of health programs and interventions. He oversaw an HIV combination prevention intervention covering a population of around 100,000 in the south of Mozambique; He has been involved in several evaluation studies including HIV, Malaria, TB, and Covid-19, and has also done consulting for international organizations. He is currently leading the HIV Platform of the National Health Observatory in Mozambique.

Presenter of 1 Presentation

 Conference Calendar

INCIDENCE OF FIRST-CHOICE ANTIRETROVIRAL TREATMENT FAILURE AMONG CHILDREN IN MOZAMBIQUE, 2019

Session Name
0580 - Oral Presentations: VIRAL INFECTIONS, DIAGNOSIS AND TREATMENT (ID 56)
Session Type
Oral Presentations
Date
Thu, 24.02.2022
Session Time
10:00 AM - 11:00 AM
Room
Sala A
Session Icon
Pre-Recorded with Live Q&A
Presenter
Lecture Time
10:00 AM - 10:10 AM

Abstract

Background

Though access to antiretroviral therapy (ART) has increased in recent years, there is limited information about the incidence of treatment failure (TF) among children in Mozambique.

Aims

We aimed to estimate the incidence of TF, the mean time to TF (MTTF), and to identify regimens associated with higher TF among children on ART, in 2019.

Methods

Data from children on ART were obtained from the national ART registry and those with TF from the national ART Committee database. The total TF incidence was calculated by dividing the number of children with TF by the total number of children on ART, in 2019. Regimen-specific incidences were obtained by multiplying the total incidence of TF by the proportion of children with TF in each regimen. The 1000-sample bootstrap was used to calculate 95% CIs.

Results

The incidence of TF was 246.0 (95% CI: 101.2-390.8) cases per 10,000 children per year. Regimens with higher incidence of TF included AZT+3TC+NVP, TDF+3TC+EFV, and ABC+3TC+NVP with 231.5 (95% CI: 96.6-366.4), 4.9 (95% CI: 2.6-7.2), and 2.2 (95% CI: 1.1-3.3) TF cases in 10,000 children per year, respectively. The MTTF was 5.4 years (95% CI: 5.2-5.6), and d4T+3TC+NVP, TDF+3TC+NVP, and AZT+3TC+LPV/r had longer MTTF of 9.5 (95% CI: 3.3-12.7), 8.3 (95% CI: 2.0-10.5), and 7.9 (95% CI: 6.2-11.8), respectively.

Conclusions

The incidence of TF among children on ART was found to be of public health concern. There is need to consider regimens containing protease inhibitors and DTG as first-choice ART among children to achieve sustained viral suppression.

Hide